drugset / Trial / NCT00942773
Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole
Non-randomizedParallel-groupOpen-label
Summary
The purpose of this study is to: * Evaluate the influence of CYP2C19 genotype on PK profiles of voriconazole.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-03
- Completion
- 2009-03
Publications
- Lee S, Gu N, Kim BH, Lim KS, Shin SG, Jang IJ, Yu KS. Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study. Clin Ther. 2012 May;34(5):1160-9. doi: 10.1016/j.clinthera.2012.03.058. Epub 2012 Apr 13.
- Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012 Feb;52(2):195-203. doi: 10.1177/0091270010395510.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Voriconazole | Small molecule | 200 mg | Intravenous |
Indications
No indication recorded.